Close

Edwards Lifesciences Corp stops small mitral heart valve study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

NHS Boards to Explore Joint Working...

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients...

The NHS in England has remained under relentless pressure...

Thermo Fisher Receives FDA Approval for...

The world leader when it comes to serving science,...

Virtual MRI Imaging with AI Aids...

During the magnetic resonance imaging (MRI) procedures, contrast agents...

Edwards Lifesciences Corp on Tuesday said it stopped enrolling patients in a small study of its less-invasive mitral heart valve device due to the formation of blood clots associated with the procedure.
The company, which introduced a catheter-based approach to replacing diseased aortic heart valves in the U.S. market in 2011, is working to adapt the technique for the mitral valve.
The experimental mitral valve, Fortis, had been implanted in more than 20 patients before it halted the study, Edwards said.
The so-called transcatheter approach to heart valve replacement, in which the valve is threaded through the arteries to the heart, spares the patient from traditional open-heart surgery.
Edwards said it voluntarily implemented a temporary pause in the program to assess valve thrombosis, or clotting, observed in patients. The company said it remains committed to transcatheter mitral valve replacement.
"While the program freeze is certainly disappointing, it doesn’t necessarily change its competitive positioning much in a market where everyone is still in the very early stages of development," J.P. Morgan analyst Michael Weinstein said in a note to clients.
The medical device maker's shares fell as much as 4.7
percent before recovering to trade at $129.61, down 1.6 percent, at midday on the New York Stock Exchange.

 

Latest stories

Related stories

NHS Boards to Explore Joint Working in Sussex and Surrey

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients Volume Grows

The NHS in England has remained under relentless pressure...

Virtual MRI Imaging with AI Aids Better Tumor Detection

During the magnetic resonance imaging (MRI) procedures, contrast agents...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back